The present invention provides a compound of formua I: ##STR00001##
wherein X.sup., R.sup.1, and R.sup.2 are as defined herein, and compositions thereof.

A multi-dimensional chromatographic method for the separation of N-glycans. The method comprises providing a glycan preparation that includes at least one negatively charged N-glycan. The glycan preparation is then separated by anion-exchange chromatography and at least one secondary chromatographic technique.

The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.

The invention is directed towards novel amino acid based compounds, which may be isotopically enriched, and methods of use of such compounds for characterizing one or more molecules of a sample by mass spectrometry, the method comprising: (a) reacting the one or more molecules with the compound; and (b) characterizing the one or more molecules by mass spectrometry.

Provided are methods of detecting the presence or amount of the active form of vitamin B6, pyridoxal 5-phosphate, in a body fluid sample using tandem mass spectrometry coupled with liquid chromatography.

The present disclosure relates to methods of administering tolperisone to subjects in need thereof. In certain aspects, the present disclosure relates to methods of administering tolperisone to subjects in need thereof, said methods limiting the exposure of the subject to 4-MMPPO.

The present invention provides a method for the analysis of a compound with amino group (e.g., an amino acid or peptide) contained in a sample and convenient manner with a high sensitivity. The compound with amino group in a sample containing the compound with amino group is labeled with a specific carbamate compound such as p-trimethylammonium anilyl-N-hydroxysuccinimidyl carbamate iodide to enhance the selectivity and sensitivity. The present invention is preferably used in conjunction with mass spectrometry such as MS/MS method to facilitate quantitative analysis. The present invention further provides labeling reagents for mass spectrometry.

Various agents for improving adhesion of cold end coatings on glass surfaces are described Also described are agents for improving bonding between cold end coatings and organic inks. And, methods and related detection solutions for detecting the presence of cold end coatings on a substrate such as a glass bottle are disclosed. Additionally, particular additives and primers are described that can be applied onto cold end coatings for improving adhesion thereto.

A personal-sized, portable explosive detection field test kit (ETK) and related methods of use. Embodiments of the disclosed ETK include a case having a closing system featuring three levels of closure which retain the case cover securely in a closed position until ready for use, while being easily opened when necessary. The ETK instructions are permanently attached to the case to prevent loss. The case includes retention features which retain the kit components until needed and protects them against loss or damage. The ETK includes one or more test tubes that are color coded and include abbreviated instructions.

Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.